Literature DB >> 210480

The effect of L-dopa and propranolol on human CSF cyclic nucleotides.

R H Belmaker, R P Ebstein, J Biederman, R Stern, M Berman, H M van Praag.   

Abstract

Human CSF cyclic AMP and cyclic GMP have been measured as possible indicators of activity of central neurotransmitter-sensitive adenylate or guanylate cyclase. In an attempt to help to identify the specific neurotransmitter systems of origin of human CSF cyclic AMP and GMP, we studied Parkinson patients with and without L-dopa therapy and schizophrenic patients before and after propranolol therapy. No effect of L-dopa or propranolol was found on CSF cyclic nucleotides. However, Parkinson patients had a 40-50% reduction of CSF cyclic AMP and a 80-90% reduction of CSF cyclic GMP compared with the schizophrenic patients. Implications of this finding are discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 210480     DOI: 10.1007/bf00427396

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  19 in total

1.  Distribution of choline acetyltransferase and glutamate decarboxylase within the substantia nigra and in other brain regions from control and Parkinsonian patients.

Authors:  K G Lloyd; H Möhler; P Heitz; G Bartholini
Journal:  J Neurochem       Date:  1975-12       Impact factor: 5.372

2.  Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients.

Authors:  R M Post; F K Goodwin
Journal:  Science       Date:  1975-10-31       Impact factor: 47.728

3.  Cyclic nucleotide-dependent protein kinases. X. An assay method for the measurement of quanosine 3',5'-monophosphate in various biological materials and a study of agents regulating its levels in heart and brain.

Authors:  J F Kuo; T P Lee; P L Reyes; K G Walton; T E Donnelly; P Greengard
Journal:  J Biol Chem       Date:  1972-01-10       Impact factor: 5.157

4.  Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor".

Authors:  J W Kebabian; G L Petzold; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1972-08       Impact factor: 11.205

5.  Central dopamine turnover in schizophrenic syndromes.

Authors:  M B Bowers
Journal:  Arch Gen Psychiatry       Date:  1974-07

6.  Cyclic adenosinemonophosphate in cerebrospinal fluid. Effects of theophylline, L-dopa and a dopamine receptor stimulant in rats.

Authors:  M Kiessling; T Lindl; H Cramer
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1975-12-22

Review 7.  Dopamine (3-hydroxytyramine) and brain function.

Authors:  O Hornykiewicz
Journal:  Pharmacol Rev       Date:  1966-06       Impact factor: 25.468

8.  Cyclic adenosine monophosphate and norepinephrine: effects on transmembrane properties of cerebellar Purkinje cells.

Authors:  G R Siggins; A P Oliver; B J Hoffer; F E Bloom
Journal:  Science       Date:  1971-01-15       Impact factor: 47.728

9.  Studies on cyclic AMP in different compartments of cerebrospinal fluid.

Authors:  D Tsang; S Lal; T L Sourkes; R M Ford; A Aronoff
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-12       Impact factor: 10.154

10.  CYCLIC AMP/*SECRETl cyclic AMP into push-pull perfusates in freely moving rats.

Authors:  J Korf; P H Boer; D Fekkes
Journal:  Brain Res       Date:  1976-09-03       Impact factor: 3.252

View more
  7 in total

Review 1.  A Role for Phosphodiesterase 11A (PDE11A) in the Formation of Social Memories and the Stabilization of Mood.

Authors:  Michy P Kelly
Journal:  Adv Neurobiol       Date:  2017

2.  The effect of propranolol treatment in shizophrenia on CSF amine metabolites and prolactin.

Authors:  R H Belmaker; R P Ebstein; H Dasberg; A Levy; G Sedvall; H M Van Praag
Journal:  Psychopharmacology (Berl)       Date:  1979-06-21       Impact factor: 4.530

3.  PDE11A regulates social behaviors and is a key mechanism by which social experience sculpts the brain.

Authors:  Shweta Hegde; Hao Ji; David Oliver; Neema S Patel; Nicolas Poupore; Michael Shtutman; Michy P Kelly
Journal:  Neuroscience       Date:  2016-08-17       Impact factor: 3.590

4.  CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis.

Authors:  Patrick Oeckl; Petra Steinacker; Stefan Lehnert; Sarah Jesse; Hans A Kretzschmar; Albert C Ludolph; Markus Otto; Boris Ferger
Journal:  PLoS One       Date:  2012-03-02       Impact factor: 3.240

Review 5.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

6.  Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression.

Authors:  Raphael Hesse; Ludwig Lausser; Pauline Gummert; Florian Schmid; Anke Wahler; Cathrin Schnack; Katja S Kroker; Markus Otto; Hayrettin Tumani; Hans A Kestler; Holger Rosenbrock; Christine A F von Arnim
Journal:  Alzheimers Res Ther       Date:  2017-03-09       Impact factor: 6.982

7.  Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications.

Authors:  Pim R A Heckman; Marlies A van Duinen; Eva P P Bollen; Akinori Nishi; Lawrence P Wennogle; Arjan Blokland; Jos Prickaerts
Journal:  Int J Neuropsychopharmacol       Date:  2016-04-02       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.